Volitionrx LTD Form 4 insider transactions

Jasmine Kway, CEO of Singapore Volition, was awarded 8,327 restricted stock units (RSUs) of VolitionRx Ltd. common stock on June 1, 2025, as part of her compensation.

VolitionRx Ltd. Director Kim Nguyen received 11,983 restricted stock units (RSUs) on June 1, 2025, in lieu of cash compensation, aligning her interests with shareholders.

VolitionRx Ltd. General Counsel Nicholas Plummer was awarded 16,086 restricted stock units as part of his compensation, vesting in three installments through August 2025.

VolitionRx Ltd.'s Chief Operating Officer, Gaetan Michel, reported a disposition of 7,835 common shares to cover tax obligations related to restricted stock unit settlement.

VolitionRx Ltd. Secretary Rodney Gerard Rootsaert reported the acquisition of 10,190 restricted stock units and the disposition of 6,408 shares for tax withholding purposes, alongside significant indirect holdings.

VolitionRx Ltd.'s CEO of Volition Veterinary, Salvatore Thomas Butera, was awarded 23,377 restricted stock units as compensation, with 11,683 shares subsequently withheld by the company to cover tax obligations.

VolitionRx Ltd.'s Chief Commercial Officer, Gael Forterre, reported the acquisition of restricted stock units as compensation and a corresponding disposition of shares for tax withholding purposes.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRX Ltd, purchased 50,000 shares of common stock at $0.43 per share on May 19, 2025.

Cameron John Reynolds, CEO of VolitionRx Ltd, reports the acquisition of 20,000 shares of common stock at a price of $0.4365 per share.

Gaetan Michel, COO of VolitionRx, reports a transaction involving the withholding of shares to cover tax obligations upon the settlement of restricted stock units.

Andrew Retter, Chief Medical Officer of VolitionRx, reports a transaction involving the withholding of shares to cover tax obligations upon the settlement of restricted stock units.

Rodney Gerard Rootsaert, Secretary of VolitionRx, reports the withholding of 5,453 common stock shares to cover tax obligations related to restricted stock units.

CEO Salvatore Thomas Butera of VolitionRx Ltd. reports acquiring and disposing of common stock related to tax obligations from restricted stock units.

Chief Commercial Officer Gael Forterre reports stock transactions related to tax obligations on restricted stock units.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, reports changes in beneficial ownership of company stock due to tax withholding obligations upon settlement of restricted stock units.

VolitionRx CEO Cameron John Reynolds purchased 181,818 shares of common stock at $0.55 per share in a registered direct offering.

Director Guy Archibald Innes reports acquisition of VolitionRx shares through a registered direct offering and discloses beneficial ownership through various trusts.

Nicholas Plummer, GC of VolitionRx, reports the acquisition of 12,483 restricted stock units (RSUs) and disposal of 177,628 common stock on March 1, 2025.

Rodney Rootsaert, Secretary of VolitionRx, reports the acquisition of 7,908 restricted stock units (RSUs) in lieu of cash compensation.

Director Kim Nguyen acquired 9,893 shares of VolitionRX Ltd. common stock in lieu of cash compensation on March 1, 2025.

Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRX Ltd, received 14,233 restricted stock units (RSUs) in lieu of cash compensation on March 1, 2025.

Director Alan Colman received 14,840 restricted stock units (RSUs) in VolitionRX Ltd in lieu of cash compensation on March 1, 2025.

Jasmine Kway, CEO of VolitionRx Singapore, received 16,708 restricted stock units (RSUs) in lieu of cash compensation on March 1, 2025.

Andrew Retter, Chief Medical Officer of VolitionRX Ltd, was awarded 10,142 restricted stock units (RSUs) on March 1, 2025, in lieu of cash compensation.

Director Ethel Rubin acquired 9,893 restricted stock units (RSUs) in VolitionRx Ltd (VNRX) on March 1, 2025, in lieu of cash compensation.

Salvatore Thomas Butera, CEO of Volition Veterinary (a subsidiary of VolitionRx Ltd), received 19,300 restricted stock units (RSUs) in lieu of cash compensation on March 1, 2025.

Gael Forterre, Chief Commercial Officer of VolitionRx, reports the acquisition of restricted stock units (RSUs) and adjustments to beneficial ownership.

Director Guy Archibald Innes receives 19,786 restricted stock units (RSUs) from VolitionRX Ltd in lieu of cash compensation.

Terig Hughes, CFO of VolitionRx Ltd, was awarded 13,969 restricted stock units (RSUs) on March 1, 2025, in lieu of cash compensation.

Director Alan Colman amended stock options at VolitionRX on January 29, 2025, involving the cancellation of old options and the grant of replacement options.